BridgeBio forms GondolaBio JV with $300M investor commitment; retains 45% stake

BridgeBio Pharma, Inc.

BridgeBio contributed early-stage programs for Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.
Investors including Viking Global, Patient Square, Sequoia, Frazier, Cormorant, and Aisling committed $300M in tranches.
CEO Neil Kumar's entity also invested; BridgeBio's initial interest ~45%, subject to dilution.
Special committee of independent directors approved with Goldman Sachs as financial advisor.
JV will research, develop, manufacture and commercialize the contributed programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.